Nanotargeted Radionuclides for Cancer Nuclear Imaging and Internal Radiotherapy
Figure 2
(a) Gamma scintigraphy of BALB/c mice bearing CT-26 tumor animal model at 24 hr and 48 hr after intravenous injection of passively nanotargeted radionuclides of 111In-DTPA-liposome (reprinted with permission from reference [70]). (b) Tumor growth inhibition with passively nanotargeted radionuclides of 111In-(VNB)-liposome on HT-29/luc tumor bearing in SCID mice animal model (reprinted with permission from reference [71]). (c) MicroSPECT/CT images of passively nanotargeted radionuclides of 188Re-liposome and 188Re-DXR-liposome targeting CT-26 bearing in BALB/c mice animal model at 1 h, 4 h, 24 h, and compare with the control (reprinted with permission from reference [72]). (d) Therapeutic efficacy of tumor volume change and survival ratio for CT-26 tumor-bearing BALB/c mice after intravenous administration of passively nanotargeted radionuclides of 188Re-(DXR)-liposome were illustrated. (reprinted with permission from reference [73]).
